BioSpace News Archive

Focus on clinical tool development to advance new treatments for neurobehavioral disorders

Providertech announced today its platform interface with Epic.

The Honourable Kirsty Duncan, Minister of Science and Sport, will announce a major investment through Genome Canada at the first ever International Wheat Congress.

InvaGen Pharmaceuticals, Inc., a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited announced the receipt of final approval for its Abbreviated New Drug Application for Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg from the United States Food and Drug Administration.

CStone Pharmaceuticals announced that it has received approval from China National Medical Products Administration to initiate a Phase I bridging registrational study of ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation.

Research partners from pharma, academia, and SMEs have come together to form the Reward Task Optimisation Consortium.

Masimo announced that in a study recently published in Anesthesia & Analgesia, researchers evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to detect the development of acute hemodilution after graded fluid administration, by comparing it to invasively measured laboratory hemoglobin, on patients undergoing major surgery.1

Vedolizumab subcutaneous is currently under review for approval for ulcerative colitis with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA)

Sanford Guide® announces the availability of its industry-leading infectious diseases guidelines through MD Labs® Results Reports.

Tiziana Life Sciences plc announced preliminary topline clinical data from a Phase 2a trial of Milciclib as a monotherapy in patients with advanced hepatocellular carcinoma, the most common form of liver cancer.